October 24, 2026 · The British journal of psychiatry : the journal of mental science · DOI: 10.1192/bjp.2026.10863

Metabolic biomarker levels before and after initiation of GLP-1 receptor agonist treatment among individuals with schizophrenia: interrupted time-series analysis.

Listen to this summary

This Danish nationwide registry study examined whether starting a GLP-1 receptor agonist was followed by improvements in metabolic markers among 3,042 individuals with schizophrenia, using interrupted time-series analysis. Among those starting treatment for diabetes, HbA1c, LDL, and triglyceride levels dropped by 11.4%, 6.2%, and 14.8%, respectively, while those starting for overweight saw reductions of 3.4%, 4.9%, and 12.7%. The findings suggest that the metabolic benefits seen in randomised trials of GLP-1 receptor agonists in schizophrenia also extend to routine clinical practice, though the observational design cannot fully rule out other explanations.

Nicoline Bach Mikkelsen, Anders Ørberg, Søren Dinesen Østergaard, Christopher Rohde

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play